Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

Trial Profile

An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Aug 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pitolisant (Primary)
  • Indications Narcolepsy
  • Focus Expanded access; Therapeutic Use
  • Acronyms PEACE
  • Sponsors Harmony Biosciences
  • Most Recent Events

    • 24 Aug 2020 According to a Harmony Biosciences media release, final analysis data from this study will be presented at the upcoming 34th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2020." The meeting is being held virtually from August 27th-30th. Abstracts of the WAKIX data will also be published in the journal SLEEP as an online supplement.
    • 02 Jun 2020 According to a Harmony Biosciences media release, data from this study were presented at the American Academy of Neurology (AAN) Science, a highlights virtual platform and were published in the journal Neurology in the "Sleep Medicine: Focus on Therapies 2" poster session.
    • 01 May 2020 Results assessing safety and tolerability were presented at the 72nd Annual Meeting of the American Academy of Neurology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top